TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31868565

Group type: EXPERIMENTAL
Intervention: 10% urea cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.025% tretinoin cream
Number of subjects: 0
Study: 31225906

Group type: EXPERIMENTAL
Intervention: Preoperative PET/CT
Number of subjects: 112
Study: 28530513

Group type: COMPARATOR
Intervention: Pre-invitation leaflet
Number of subjects: 20105

Group type: COMPARATOR
Intervention: Online booking
Number of subjects: 20105

Group type: EXPERIMENTAL
Intervention: Self-sample kits sent unrequested
Number of subjects: 20105

Group type: EXPERIMENTAL
Intervention: Timed appointments
Number of subjects: 20105

Group type: EXPERIMENTAL
Intervention: Nurse navigator
Number of subjects: 20105

Group type: EXPERIMENTAL
Intervention: Self-sample kits on request
Number of subjects: 20105

Group type: EXPERIMENTAL
Intervention: Choice between timed appointments and nurse navigator
Number of subjects: 20105
Study: 26487668

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 632

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 632
Study: 25741456

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22574591

Group type: EXPERIMENTAL
Intervention: Shuxuening Injection (SI), 15 mL by intravenous dripping, twice daily for 14 days
Number of subjects: 79

Group type: COMPARATOR
Intervention: Routine therapies for COPD (Control)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Shuxuening Injection (SI)
Number of subjects: 79
Study: 20367846

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study: 19093172

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esophagectomy with three-field lymph node dissection
Number of subjects: 0
Study: 16013622

Group type: EXPERIMENTAL
Intervention: Repeated video feedback over 3 consecutive weekly practice sessions
Number of subjects: 33

Group type: COMPARATOR
Intervention: No videotaped feedback (control group)
Number of subjects: 33
Study: 12052669

Group type: EXPERIMENTAL
Intervention: Ecstasy users (MDMA)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 94
Study: 10606227

Group type: EXPERIMENTAL
Intervention: V89L polymorphism (leu/val and leu/leu genotypes)
Number of subjects: 799

Group type: COMPARATOR
Intervention: AAG levels
Number of subjects: 799
Study: 8959943

Group type: EXPERIMENTAL
Intervention: Deferiprone (3-6 g daily)
Number of subjects: 38
Study: 1797517

Group type: COMPARATOR
Intervention: Lottery tickets for CO reduction (0-3 tickets per day based on CO reduction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine gum and lottery tickets (up to 5 tickets per night for CO < 10 ppm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Special reinforcement schedules (up to 20 tickets per night for CO < 10 ppm)
Number of subjects: 0
Study: 6720626

Group type: EXPERIMENTAL
Intervention: High P/S ratio diet for 6 weeks followed by low P/S ratio diet for 6 weeks
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low P/S ratio diet for 12 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low P/S ratio diet for 6 weeks followed by high P/S ratio diet for 6 weeks
Number of subjects: 3
Study: 30421019

Group type: EXPERIMENTAL
Intervention: Decision tree model using contrast-enhanced MRI-derived quantitative radiomic features
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Decision tree model with two features (S(1, -1) Entropy and S(2, -2) SumAverg)
Number of subjects: 66
Study: 29727906

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin for one month (TP1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin for one month (TP2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Dapagliflozin and saxagliptin combination
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control during TP2)
Number of subjects: 26
Study: 27565832

Group type: EXPERIMENTAL
Intervention: Culturally Adapted Motivational Interviewing (CAMI)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Motivational Interviewing (MI)
Number of subjects: 257
Study: 24710957

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg·kg(‐1) with sugammadex 4.0 mg·kg(‐1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg·kg(‐1)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Rocuronium followed by sugammadex
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 150
Study: 20009394

Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based triple therapy
Number of subjects: 772

Group type: COMPARATOR
Intervention: Clarithromycin-based triple therapy
Number of subjects: 772
Study: 15037942

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11679006

Group type: EXPERIMENTAL
Intervention: tazarotene gel 0.1%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: tazarotene vehicle
Number of subjects: 24

Group type: COMPARATOR
Intervention: diflorasone diacetate 0.05% ointment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: diflorasone diacetate 0.05% ointment + tazarotene gel 0.1%
Number of subjects: 24
Study: 9490342

Group type: EXPERIMENTAL
Intervention: Neoton (4 different schemes) administered in the acute period of MI to 97 patients.
Number of subjects: 174
Study: 7965552

Group type: EXPERIMENTAL
Intervention: CPC/essential oil rinse (two variations)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer product
Number of subjects: 200

Group type: COMPARATOR
Intervention: Hydroalcohol negative control
Number of subjects: 200
Study: 2977404

Group type: EXPERIMENTAL
Intervention: Low-dose captopril (6.25 mg twice daily)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose captopril (25 mg twice daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31020392

Group type: COMPARATOR
Intervention: Homoeopaths (hom)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Nutritional Therapists (NT)
Number of subjects: 144
Study: 30113228

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 387
Study: 27364808

Group type: EXPERIMENTAL
Intervention: Collaborative care model (offsite depression care team)
Number of subjects: 263
Study: 24325386

Group type: EXPERIMENTAL
Intervention: Carnitine (1000 mg oral solution twice daily for 4 weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (10 mL oral solution twice daily for 4 weeks)
Number of subjects: 116
Study: 22390884

Group type: EXPERIMENTAL
Intervention: Wire osteosynthesis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mini plate osteosynthesis
Number of subjects: 80
Study: 19022322

Group type: EXPERIMENTAL
Intervention: Smallpox vaccination
Number of subjects: 90
Study: 17869987

Group type: EXPERIMENTAL
Intervention: Ethylene oxide sterilization (E1 group - once, E2 group - twice, E3 group - three times)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde sterilization (G1 group - 150 minutes, G2 group - 300 minutes, G3 group - 450 minutes, G4 group - 600 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated ETTs)
Number of subjects: 0
Study: 15028552

Group type: EXPERIMENTAL
Intervention: Immediate 12-week parent and child treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Delayed-treatment condition (control)
Number of subjects: 47
Study: 11404721

Group type: EXPERIMENTAL
Intervention: Triple therapy (amoxicillin, clarithromycin, pantoprazole)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Triple therapy (tinidazole, clarithromycin, ranitidine bismuth citrate)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Triple therapy (tinidazole, clarithromycin, pantoprazole)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (tinidazole, tetracycline, bismuth, pantoprazole)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Triple therapies
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: H. pylori reinfection in IDDM patients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Daily insulin requirement in re-infected IDDM patients
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Glicate haemoglobin in re-infected IDDM patients
Number of subjects: 116
Study: 9591000

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Small incision cholecystectomy (SC)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 200
Study: 7869318

Group type: EXPERIMENTAL
Intervention: Signal method of measurement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aggregate method of measurement
Number of subjects: 70
Study: 3337028

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (1.6 mg Fe/100 kcal)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nonfortified formula
Number of subjects: 2
Study: 29392371

Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27488675

Group type: EXPERIMENTAL
Intervention: VR-CAP (bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)
Number of subjects: 0
Study: 25626749

Group type: COMPARATOR
Intervention: Flawless demonstration (F)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mixed flawless and errorful performances (E)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Flawless and errorful performances with assessment feedback (FA)
Number of subjects: 39
Study: 23582626

Group type: EXPERIMENTAL
Intervention: Benazepril 40 mg and Amlodipine 10 mg (B+A)
Number of subjects: 5714

Group type: COMPARATOR
Intervention: Benazepril 40 mg and Hydrochlorothiazide 25 mg (B+H)
Number of subjects: 5714
Study: 21135284

Group type: EXPERIMENTAL
Intervention: Amrubicin (40 mg/m²/d in a 5-minute IV infusion, days 1 through 3, every 21 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m²/d in a 30-minute IV infusion, days 1 through 5, every 21 days)
Number of subjects: 76
Study: 18766378

Group type: EXPERIMENTAL
Intervention: G10 formula (AHE-based product)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Ethanolic DEET solution (25% DEET)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Insect Block 28 (28.5% DEET)
Number of subjects: 27
Study: 17062213

Group type: EXPERIMENTAL
Intervention: RV-PA conduit
Number of subjects: 17

Group type: COMPARATOR
Intervention: BT shunt
Number of subjects: 17
Study: 12860545

Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament injury
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (uninjured teammates)
Number of subjects: 33
Study: 10969352

Group type: EXPERIMENTAL
Intervention: Triple antiretroviral therapy
Number of subjects: 37303

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 37303

Group type: COMPARATOR
Intervention: Not prescribed antiretroviral therapy
Number of subjects: 37303

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 37303
Study: 9177388

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 1438618

Group type: EXPERIMENTAL
Intervention: MCPP (0.25 mg/kg, p.o.)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: DMI (75 mg, i.m.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Total sample (including all groups)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patients with major depression and panic disorder
Number of subjects: 49
Study: 3514648

Group type: EXPERIMENTAL
Intervention: Logistic model for defining high-risk subgroup
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Selection strategy for screening
Number of subjects: 77
Study: 31526825

Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 184

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 184
Study: 29153963

Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography (SWE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: B-mode Ultrasound (B-US)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Power Doppler Ultrasound (PD-US)
Number of subjects: 35
Study: 26871460

Group type: EXPERIMENTAL
Intervention: Long-term meditation practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-week course of mindfulness-based stress reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different types of meditation practices
Number of subjects: 0
Study: 24782083

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study: 22516385

Group type: EXPERIMENTAL
Intervention: Aluminum-based antiperspirant
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard care (wash only)
Number of subjects: 198
Study: 20150294

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Metformin (2000 mg/day)
Number of subjects: 78
Study: 17873551

Group type: EXPERIMENTAL
Intervention: Low-intensity walking program (3 times per week for 3 months, 30 minutes per session)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 32
Study: 16251172

Group type: EXPERIMENTAL
Intervention: Increasing dosage of rh‐EPO up to 5000 U/kg/wk
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard therapy of rh‐EPO at 1250 U/kg/wk
Number of subjects: 51
Study: 11912262

Group type: EXPERIMENTAL
Intervention: Angiotensin I infusion (8 ng/kg per min) with liberal sodium intake (200 mmol sodium/d)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Angiotensin I infusion (8 ng/kg per min) with low sodium intake (50 mmol sodium/d)
Number of subjects: 27
Study: 10444229

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diphenhydramine (first-generation antihistamine)
Number of subjects: 0
Study: 7600138

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg at 0.1 mg/min infusion rate)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2195865

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 7100
Study: 631690

Group type: EXPERIMENTAL
Intervention: Berotec syrup 2.5 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Berotec syrup 5.0 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 30394106

Group type: EXPERIMENTAL
Intervention: Culturally-targeted 1:1 intervention (Desi-Sehat) delivered in English, Hindi, and Urdu
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Culturally-targeted 1:1 intervention (Desi-Sehat)
Number of subjects: 93
Study: 30745346

Group type: EXPERIMENTAL
Intervention: Mobile augmented reality simulator used for local anesthesia training, 2 hours weekly for four weeks.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mobile augmented reality simulator
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional educational methods (Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 29169472

Group type: EXPERIMENTAL
Intervention: Inhaled xenon (40% end-tidal concentration) combined with hypothermia (33°C) for 24 hours
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hypothermia treatment alone
Number of subjects: 110
Study: 25780939

Group type: EXPERIMENTAL
Intervention: Partnership support program
Number of subjects: 318

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 318
Study: 23739030

Group type: EXPERIMENTAL
Intervention: IOP plus 12 months of enhanced continuing care (ECC)
Number of subjects: 152

Group type: COMPARATOR
Intervention: IOP treatment as usual (TAU)
Number of subjects: 152
Study: 20865421

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (first-time)
Number of subjects: 90
Study: 20218030

Group type: EXPERIMENTAL
Intervention: Diabetes Check intervention (5 to 10 interactions)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control activity (2 drug-profile reviews)
Number of subjects: 130
Study: 17094752

Group type: EXPERIMENTAL
Intervention: Tubeless procedure using a tailed 6F double-J stent
Number of subjects: 24

Group type: COMPARATOR
Intervention: Small tube procedure using an 8.2 pigtail nephrostomy tube
Number of subjects: 24
Study: 15998166

Group type: EXPERIMENTAL
Intervention: Intervention arm (letter notification)
Number of subjects: 6518

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 6518
Study: 11376174

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 160

Group type: COMPARATOR
Intervention: No radiotherapy, second surgery, or chemotherapy
Number of subjects: 160
Study: 9279624

Group type: EXPERIMENTAL
Intervention: One or more doses of BCG vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One dose of BCG vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of BCG vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three doses of BCG vaccine
Number of subjects: 0
Study: 7509619

Group type: EXPERIMENTAL
Intervention: CHOP-based chemotherapy
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Prognostic index
Number of subjects: 281
Study: 3534212

Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine HCl
Number of subjects: 20
Study: 2545451

Group type: EXPERIMENTAL
Intervention: RIT-4237 rotavirus vaccine
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 31892639

Group type: EXPERIMENTAL
Intervention: COPDAE+ (severe acute exacerbation of COPD)
Number of subjects: 3734

Group type: EXPERIMENTAL
Intervention: COPDAE- (no acute exacerbation of COPD)
Number of subjects: 3734

Group type: COMPARATOR
Intervention: non-COPD (control group)
Number of subjects: 3734

Group type: EXPERIMENTAL
Intervention: COPDAE+ (aged <65)
Number of subjects: 3734
Study: 30698771

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (3 sessions)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prolotherapy with 20% dextrose (1 session)
Number of subjects: 33
Study: 29119960

Group type: EXPERIMENTAL
Intervention: Low-frequency electrostatic therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 94
Study: 25850708

Group type: EXPERIMENTAL
Intervention: Topical Loteprednol Etabonate 0.5%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cyclosporine A 0.05%
Number of subjects: 75
Study: 23800263

Group type: EXPERIMENTAL
Intervention: Auditory stress
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 22079655

Group type: EXPERIMENTAL
Intervention: ¹²³I‐ADAM SPECT imaging over 1 month
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ¹²³I‐ADAM SPECT imaging over 1 year
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of test-retest scans
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Circadian correlation analysis
Number of subjects: 28
Study: 19920107

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (100 mcg/kg, single dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Filgrastim (5 mcg/kg/day, daily until neutrophil recovery)
Number of subjects: 34
Study: 16491284

Group type: EXPERIMENTAL
Intervention: Pamidronate treatment (annual dose, 9 mg/kg body weight) for 2-4 years
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated OI patients (matched for OI type and age)
Number of subjects: 50
Study: 15187818

Group type: EXPERIMENTAL
Intervention: Wheat fibre supplementation (10.5 g/day for 1 week, then 21 g/day for 4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (standard high-fibre diet)
Number of subjects: 42
Study: 11068116

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 130
Study: 9248263

Group type: EXPERIMENTAL
Intervention: 0.5 w/v% black tea extract gargle twice daily (at 8 a.m. and 5 p.m.)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Normal daily routine (control group)
Number of subjects: 259
Study: 8448094

Group type: EXPERIMENTAL
Intervention: Low-dose epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 30
Study: 2427841

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg once daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 to 400 mg once daily)
Number of subjects: 55
Study: 31301881

Group type: EXPERIMENTAL
Intervention: UHR group
Number of subjects: 285
Study: 30281106

Group type: EXPERIMENTAL
Intervention: Growing-Up Milk (GUMLi)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cow Milk (CM)
Number of subjects: 160
Study: 28409398

Group type: EXPERIMENTAL
Intervention: Positive pacing strategy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Negative pacing strategy
Number of subjects: 15
Study: 25680597

Group type: EXPERIMENTAL
Intervention: Pelvic external beam radiation therapy (EBRT)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT)
Number of subjects: 1240

Group type: EXPERIMENTAL
Intervention: No adjuvant treatment
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1240
Study: 23553459

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg, twice daily) for 12 weeks
Number of subjects: 107
Study: 20384441

Group type: EXPERIMENTAL
Intervention: hp-hMG
Number of subjects: 136

Group type: COMPARATOR
Intervention: r-FSH
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: r-FSH + hp-hMG
Number of subjects: 136
Study: 18445988

Group type: EXPERIMENTAL
Intervention: imidafenacin 0.1 mg twice daily
Number of subjects: 14
Study: 17028508

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 183
Study: 12756930

Group type: EXPERIMENTAL
Intervention: 4 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 6 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (4 weeks and 6 weeks of physical therapy)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 4 weeks of physical therapy
Number of subjects: 26
Study: 10418715

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 20